Chugai Pharmaceutical (OTCMKTS:CHGCY) Issues Earnings Results

Key Points

• EPS $0.22: Chugai reported quarterly earnings of $0.22 per share, with a return on equity of 22.00% and a net margin of 34.47%.
• Shares fell about 1.4% to $27.48 on Friday on volume of 63,620; the stock has a market cap of $90.44 billion, a P/E of 31.58, and a 12‑month range of $19.50–$34.84.
• Analyst sentiment has improved recently, with SMBC Nikko and UBS upgrading the stock to a Strong Buy and the consensus rating currently listed as Strong Buy.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) issued its quarterly earnings data on Friday. The company reported $0.22 earnings per share (EPS) for the quarter, Zacks reports. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.

Chugai Pharmaceutical Stock Down 1.4%

OTCMKTS CHGCY traded down $0.40 on Friday, reaching $27.48. 63,620 shares of the stock traded hands, compared to its average volume of 204,659. The firm's fifty day simple moving average is $28.98 and its 200 day simple moving average is $27.01. The company has a market cap of $90.44 billion, a price-to-earnings ratio of 31.58 and a beta of 0.69. Chugai Pharmaceutical has a 12 month low of $19.50 and a 12 month high of $34.84.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Smbc Nikko Sec. raised Chugai Pharmaceutical to a "strong-buy" rating in a report on Wednesday, February 25th. UBS Group raised Chugai Pharmaceutical to a "strong-buy" rating in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Strong Buy".

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai's activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.